13 pharmaceutical tycoons are listed in the Advisory Committee of science and Technology Innovation Board

[China Pharmaceutical network industry news] on April 4, the Shanghai Stock Exchange issued the announcement on the appointment of the members of the Shanghai Stock Exchange's science and Technology Innovation Advisory Committee, and 13 experts related to the pharmaceutical field were selected Among them, 7 medical experts, researchers and 6 people related to medical investment Ding Jian, academician of Chinese Academy of engineering and tumor pharmacology expert, is engaged in the R & D and creation of new anti-tumor drugs As one of the main R & D candidate drugs with independent intellectual property rights, Ding Jian is in clinical phase I-III clinical research at home and abroad, two new drugs are applying for clinical application, and another batch of candidate drugs are in systematic preclinical research Ding Jian is currently president of the College of pharmacy, Chinese Academy of Sciences, member of the special committee for life and health of the academic committee of Chinese Academy of Sciences, and director of the academic committee of Shanghai Institute of pharmacy, Chinese Academy of Sciences Jiang Hualiang, academician of the Chinese Academy of Sciences and expert in pharmaceutical science, is engaged in the development and application of new methods and technologies in interdisciplinary fields such as biology, chemistry, computer science and information science, and in-depth research on drug design, discovery of new drug targets, relationship between conformational changes of drug targets and pharmacological functions Jiang Hualiang cooperates with others in the development and research of new drugs Several candidate new drugs enter the clinical research or obtain the clinical approval, and realize the technology transformation Xia Ningshao, Dean of School of public health, Xiamen University, is mainly engaged in the research of viral molecular biology and genetic engineering, and has been engaged in the research of biomedical basic research and biomedical transformation for a long time, and has made a series of achievements in the research of infectious disease prevention and control Qin Shukui, chief physician, professor and doctoral supervisor, has been engaged in the clinical and scientific research work of oncology for a long time, and is good at the drug treatment of digestive system tumors and bone metastases Qin Shukui served as the director of the international society of tumor immunology, executive director of the Asian Society of Clinical Oncology, vice president of the Chinese society of Clinical Oncology, President of the Beijing CSCO foundation, etc Li Peng, academician of Chinese Academy of Sciences and molecular physiologist, has been engaged in the research of lipid metabolism and metabolic diseases for a long time It has opened up a new research direction in the field of lipid metabolism Its research work provides new ideas and strategies for the clinical treatment of obesity, fatty liver and insulin resistance The research results are highly recognized by the international and domestic Li Jin, chief physician, professor and doctoral supervisor, served as the director of biotherapy research center of Fudan University Cancer Hospital, the director of Clinical Drug Research Institute of Fudan University Cancer Hospital, and the director of Shanghai chemotherapy quality control center He is also vice president of the Asian Cancer Alliance, member of the cancer doctor qualification examination committee of the Ministry of health, Secretary General of the Chinese society of Clinical Oncology, etc Professor Shi Yuankai, chief physician, is now Deputy Secretary of the Party committee and deputy director of internal medicine of Cancer Hospital of Chinese Academy of Medical Sciences It has rich experience in medical treatment of malignant lymphoma, breast cancer, lung cancer, gastrointestinal cancer and other tumors, especially good at hematopoietic stem cell transplantation Founder, chairman and executive officer of Li Ge yaomingkant Li Ge is a senior chemist in the field of combinatorial chemistry and pharmaceutical chemistry He has successfully used "combinatorial chemistry technology" to discover a variety of drug precursor compounds, three of which have entered clinical trials in different stages in the United States He has more than 40 invention monographs and published many academic papers in the industry Journal Zhang Lianshan, deputy general manager of Hengrui pharmaceutical, worked in Lilly, USA from March 1998 to July 2008 He has served as chemist, research scientist and research consultant for many research projects From July 2008 to April 2010, he served as the chemical director of us marcadia biotechnology company, and joined Hengrui pharmaceutical in May 2010 Bao fan, executive director and executive officer of Huaxing capital, has successively served Morgan Stanley and Credit Suisse He has seven years of experience in investment banking on Wall Street, helping several multinational enterprises in fund raising, bank lending, merger and acquisition, etc In 2004, Huaxing capital group was founded Shen NANPENG, global executive partner of Sequoia Capital, is currently chairman of Yale China Center Council, director of Yabuli China entrepreneur forum, vice chairman of venture capital Professional Committee of China Securities Investment Fund Association, member of Hong Kong Financial Development Bureau, director of Brookings Institution, director of Asia Association, etc As an institution focusing on long-term structural value investment, the founder and executive officer of Hillhouse Capital Group has become one of the investment funds with large asset management scale in Asia after more than ten years of development Before Zhang Jiang, the managing director of Ping An venture capital, participated in the establishment of Ping An venture capital, Zhang Jiang served as a strategic consultant in McKinsey, mainly providing strategic consulting for the medical and financial industries He has been engaged in product research and development and marketing at Philips Medical Netherlands headquarters.